OPEN INNOVATION PLATFORM – Beyond the Rule of Five: Scouting for Novel Formulation Approaches to Enable the Subcutaneous Application of Molecules With Poor Drug-Like Properties in Preclinical Research – Facilitated Through opnMe.com
Ines Truebenbach, PhD; Menorca Chaturvedi, PhD; Markus Koester, PhD; and Achim Grube, PhD, are looking for proposals that would provide innovative formulation approaches to facilitate the subcutaneous application of bRo5 molecules in a preclinical setting.
Dr. Paul Shields, COO of Enteris BioPharma, discusses the changing face of the CDMO industry and how his company plans to leverage its newly expanded CDMO operations to take advantage of a variety of growth opportunities to build deeper partnerships.
PRODUCT DEVELOPMENT STRATEGY – ESCP, Estimating Product Performance Part 4 – Building Playgrounds & Fences
Josef Bossart, PhD, introduces, in a series of short articles, a qualitative model to help understand and visualize the potential of a product with prescribers, patients, and payors. This simple model can help weed out product ideas that may at first glance seem attractive but offer little potential in the real world.
Ashley Jacobi says while there are many ever-improving tools available to scientists performing ground-breaking research, and the potential of CRISPR genome editing appears limitless, there remain challenges that need to be overcome to realize the technology’s full potential.
Robert Davidson says there have been significant advances in clinical development of this novel drug delivery system, and the technology is rapidly moving from just a theory to practical real-world application.
DRUG DEVELOPMENT EXECUTIVE – Quotient Sciences: Breaking Down the Silos Between Drug Substance & Drug Product
Mark Egerton, PhD, CEO of Quotient Sciences, discusses how integrating these capabilities cuts through functional silos, simplifies drug development, and affirms Quotient’s belief that molecules need to become cures, fast.
GLOBAL REPORT – 2020 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery and Formulation Pipeline
In part 4 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, provides pipeline snapshots and comparisons for a number of parameters that are of most interest to drug delivery and formulation professionals – Disease Area, Molecule Type, and Delivery Route.
This white paper describes the use of PVA-based Parteck® SRP 80, a functional excipient specifically developed for matrix-based sustained release oral solid dose formulations.
Celanese and ThermoFisher Scientific have partnered together to present the value of the VitalDose® EVA drug delivery platform and manufacturing through Hot Melt Extrusion (HME) on September 9, 2021.
FORMULATION FORUM – A Quick Approach for Evaluation of Drug-Excipient Compatibility: Case of Acetylsalicylic Acid
In this study, the authors monitor acetylsalicylic acid (ASA) hydrolysis in different formulations using UPLC and TAM with the objective of comparing these methods for agreement, speed, and efficiency in predicting drug stability. In parallel, they assess the impact of the excipient choices on the stability of the ASA.
EXCLUSIVE ONLINE CONTENT
Inc. magazine revealed that Ascendia Pharmaceuticals rose 3,239 positions on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies…..
PCI Pharma Services Announces the Acquisition of LSNE to Add End-to-End Global Sterile Fill-Finish & Lyophilization Manufacturing Capabilities
PCI Pharma Services (PCI) recently announced it has signed a definitive agreement to acquire Lyophilization Services of New England, Inc. (LSNE), a premier contract development and manufacturing organization (CDMO)….
Pace Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services
Pace Analytical Life Sciences, LLC, a subsidiary of Pace Analytical Services, LLC, a full-service contract development and manufacturing organization (CDMO), recently announced that it has acquired Velesco….
Centogene & Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
Centogene N.V. and Twist Bioscience Corporation recently announced they have signed a contract to collaborate on the development and commercialization of custom assay kits for rare diseases…..
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA recently announced the US FDA has accepted for filing the New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for the….